Itai Hecht - Medivie Therapeutic CEO
| MDVI Stock | ILA 83.40 0.10 0.12% |
CEO
Mr. Itai Hecht serves as Chief Executive Officer of a Subsidiary of Medivie Therapeutic Ltd effective February 20, 2018. The Subsidiary is called HiPharma Ltd. His work experience includes the role of Vice Manager at Sewage Treatment PlantPalgey Sharon . He holds a Bachelors degree in Geography and Environmental Studies from Haifa University. Additionally, he holds a High National Diploma in Water and Soil Studies from Rupin College. since 2018.
| Age | 37 |
| Tenure | 6 years |
| Phone | 44 8708 200 096 |
| Web | http://www.medivie.com |
Medivie Therapeutic Management Efficiency
The company has return on total asset (ROA) of (1.0886) % which means that it has lost $1.0886 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5598) %, meaning that it generated substantial loss on money invested by shareholders. Medivie Therapeutic's management efficiency ratios could be used to measure how well Medivie Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Uzi Yaari | Magic Software Enterprises | 45 | |
| Ofer Greenberger | Orbit Technologies | 52 | |
| Igal Zamir | TAT Technologies | 57 | |
| Ben Weinberger | Orbit Technologies | 53 | |
| Guy Bernstein | Magic Software Enterprises | 55 | |
| Yakov Tsaroya | Magic Software Enterprises | 53 | |
| Eyal Adi | One Software Technologies | 53 | |
| Eitan Livneh | Orbit Technologies | 63 | |
| Hanan Shahaf | Magic Software Enterprises | 67 | |
| Adi Eyal | One Software Technologies | 64 | |
| Shmuel Koren | Orbit Technologies | 41 | |
| Yuval Baruch | Magic Software Enterprises | 56 | |
| Yacov Tsruya | Magic Software Enterprises | 43 | |
| Aviad Shein | One Software Technologies | 53 | |
| Shai Ozon | One Software Technologies | 42 | |
| Moshe Gez | Magic Software Enterprises | 52 | |
Management Performance
| Return On Equity | -1.56 | |||
| Return On Asset | -1.09 |
Medivie Therapeutic Leadership Team
Elected by the shareholders, the Medivie Therapeutic's board of directors comprises two types of representatives: Medivie Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medivie. The board's role is to monitor Medivie Therapeutic's management team and ensure that shareholders' interests are well served. Medivie Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medivie Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Omri Wolf, Internal Auditor | ||
| Irit BenAmi, External Director | ||
| Itai Hecht, Chief Executive Officer of the Company’s Subsidiary | ||
| Uri BenOr, Vice President - Finance | ||
| Yigal Fatran, External Director | ||
| Uri Or, Chief Officer | ||
| Pr MBBS, Chief Scientist | ||
| Eyal Paauw, Independent Director | ||
| Yigal Hevroni, Chairman of the Board | ||
| Menachem Cohen, Chief Executive Officer, Director | ||
| Asher Holzer, Director |
Medivie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medivie Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.56 | |||
| Return On Asset | -1.09 | |||
| Operating Margin | (24.81) % | |||
| Current Valuation | 47.6 M | |||
| Shares Outstanding | 2.88 M | |||
| Shares Owned By Insiders | 72.29 % | |||
| Price To Book | 10.59 X | |||
| Price To Sales | 71.11 X | |||
| Revenue | 491 K | |||
| Gross Profit | (603 K) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Medivie Therapeutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Medivie Therapeutic's short interest history, or implied volatility extrapolated from Medivie Therapeutic options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medivie Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Medivie Stock analysis
When running Medivie Therapeutic's price analysis, check to measure Medivie Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medivie Therapeutic is operating at the current time. Most of Medivie Therapeutic's value examination focuses on studying past and present price action to predict the probability of Medivie Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medivie Therapeutic's price. Additionally, you may evaluate how the addition of Medivie Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |